for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aeglea Bio Therapeutics Inc

AGLE.OQ

Latest Trade

7.41USD

Change

-0.42(-5.36%)

Volume

17,802

Today's Range

7.30

 - 

7.75

52 Week Range

5.99

 - 

9.43

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Aeglea Biotherapeutics Reports Third Quarter 2019 Financial Results And Corporate Highlights

Nov 6 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.AEGLEA BIO THERAPEUTICS - AS OF SEPT 30, AEGLEA HAD AVAILABLE CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH OF $90.2 MILLION.AEGLEA BIO THERAPEUTICS - MANAGEMENT BELIEVES IT HAS SUFFICIENT CAPITAL RESOURCES TO FUND ANTICIPATED OPERATIONS THROUGH Q1 2021.QTRLY LOSS PER SHARE $0.66.Q3 EARNINGS PER SHARE VIEW $-0.54 -- REFINITIV IBES DATA.

Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium

Sept 3 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS ANNOUNCES POSITIVE 20-DOSE DATA FOR PEGZILARGINASE IN PATIENTS WITH ARGINASE 1 DEFICIENCY AT THE 2019 SSIEM SYMPOSIUM.AEGLEA BIO THERAPEUTICS - 10 PATIENTS DOSED SUBCUTANEOUSLY (SC) WITH PEGZILARGINASE IN ONGOING OLE TRIAL IN PATIENTS WITH ARG1-D.AEGLEA BIO THERAPEUTICS- EXPECTS TO CONTINUE DISCUSSIONS WITH FDA ON PEGZILARGINASE PROGRAM AND NEXT STEPS IN Q4 2019 OR Q1 2020.AEGLEA BIO THERAPEUTICS INC - EXPECTS TO REPORT TOPLINE DATA FROM PIVOTAL PEACE TRIAL IN Q1 OF 2021.

Aeglea Biotherapeutics Reports Second Quarter 2019 Financial Results And Corporate Highlights

Aug 6 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.AEGLEA BIO THERAPEUTICS - AS OF JUNE 30, 2019, CO HAD AVAILABLE CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH OF $107.0 MILLION.AEGLEA BIO THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.55.

Aeglea Biotherapeutics Receives FDA Breakthrough Therapy Designation For Pegzilarginase

July 24 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR PEGZILARGINASE FOR TREATMENT OF ARGINASE 1 DEFICIENCY.AEGLEA BIO THERAPEUTICS INC - EXPECTS TO CONTINUE DISCUSSIONS WITH FDA ON PEGZILARGINASE PROGRAM AND NEXT STEPS IN Q4 OF 2019.

Aeglea Biotherapeutics Reports Q1 Loss Per Share $0.59

May 7 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.AEGLEA BIO THERAPEUTICS INC - PIVOTAL PHASE 3 TRIAL OF PEGZILARGINASE FOR ARG1-D ON TRACK FOR FIRST PATIENT DOSING DURING 2Q19.AEGLEA BIO THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.59.AEGLEA BIO THERAPEUTICS INC - GROSS PROCEEDS OF $69 MILLION FROM FEBRUARY 2019 PUBLIC OFFERING EXTENDS CASH RUNWAY THROUGH Q1 OF 2021.AEGLEA BIO THERAPEUTICS INC - AS OF MARCH 31, 2019, AEGLEA HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $123.7 MILLION.

Aeglea Biotherapeutics Reports Fourth Quarter And Full Year 2018 Financial Results

March 7 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.AEGLEA BIO THERAPEUTICS INC - ON TRACK TO DOSE FIRST PATIENT IN PIVOTAL PHASE 3 TRIAL OF PEGZILARGINASE FOR ARG1-D IN Q2 OF 2019.AEGLEA BIO THERAPEUTICS INC - PROGRESS WITH PEGZILARGINASE CANCER INDICATION-PHASE 2 COMBINATION STUDY INITIATED.AEGLEA BIO THERAPEUTICS INC - AS OF DECEMBER 31, 2018, AEGLEA HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $74.5 MILLION.

Aeglea Bio Therapeutics Says Co Intends To Offer And Sell Up To $50 Mln Of Shares Of Its Common Stock

Feb 5 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AEGLEA BIO THERAPEUTICS INC - INTENDS TO OFFER AND SELL UP TO $50.0 MILLION OF SHARES OF ITS COMMON STOCK.AEGLEA BIO THERAPEUTICS - INTENDS TO USE PROCEEDS TO ADVANCE CLINICAL DEVELOPMENT OF PEGZILARGINASE THROUGH PHASE 3 PIVOTAL, EXTENSION TRIALS IN ARGINASE 1 DEFICIENCY.

Aeglea Bio Therapeutics Entered Master Services Agreement With Fujifilm Units

Nov 29 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIO THERAPEUTICS - ON NOVEMBER 26, ENTERED MASTER SERVICES AGREEMENT WITH FUJIFILM UNITS - SEC FILING.AEGLEA BIO THERAPEUTICS - FUJIFILM WILL PROVIDE RESEARCH, DEVELOPMENT, TESTING & MANUFACTURING SERVICES OF CERTAIN OF CO'S PRODUCTS.

Aeglea Biotherapeutics Qtrly Net Loss $0.54

Nov 8 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.AEGLEA BIO THERAPEUTICS INC - AS OF SEPTEMBER 30, 2018, CO HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $64.7 MILLION.AEGLEA BIO THERAPEUTICS INC QTRLY NET LOSS $0.54.

Aeglea Biotherapeutics Announces Positive Interim Clinical Data

Oct 17 (Reuters) - Aeglea Bio Therapeutics Inc <AGLE.O>::AEGLEA BIOTHERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM CLINICAL DATA AND IMPROVEMENTS IN DISEASE MANIFESTATIONS FOR ONGOING PHASE 1/2 TRIAL OF PEGZILARGINASE IN PATIENTS WITH ARGINASE 1 DEFICIENCY.AEGLEA BIO THERAPEUTICS INC - CLINICALLY SIGNIFICANT IMPROVEMENTS AFTER EIGHT DOSES INCLUDED EFFECTS ON MOBILITY AND ADAPTIVE BEHAVIOR.AEGLEA BIO THERAPEUTICS INC - PEGZILARGINASE IS EFFECTIVE IN SUSTAINABLY LOWERING PLASMA ARGININE LEVELS.AEGLEA BIO THERAPEUTICS INC - PEGZILARGINASE WAS WELL TOLERATED.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up